Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist.

ABSTRACT:

Background

Interleukin-17A (IL17A) is a proinflammatory cytokine critically involved in autoimmune diseases, and monoclonal antibodies of IL17A have been approved for clinical treatment of psoriasis. However, a usable psoriatic animal model has been always required for preclinical evaluation of IL17A antagonists. Imiquimod (IMQ)-induced psoriasis model is widely used in fundamental research, but it's not able to accurately show anti-psoriatic effect of IL17A antagonists with conventional modelling condition.

Results

On female C57BL/6 mice, with optimization on the usage of IMQ, positive control reagent and anti-mIL17A antibody, a 7-day model with proper testing window, acceptable disease severity as well as high repeatability was developed, and the efficacy of IL17A antagoni

SUBMITTER: Li Q 

PROVIDER: S-EPMC7844923 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature